Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non–small-cell lung cancer

Tateaki Naito(Shizuoka Cancer Center), Taro Okayama, Takashi Aoyama, Takuya Ohashi(Shizuoka General Hospital), Yoshiyuki Masuda, Madoka Kimura(Shizuoka Cancer Center), H Shiozaki, Haruyasu Murakami(Shizuoka Cancer Center), Hirotsugu Kenmotsu(Shizuoka Cancer Center), Tetsuhiko Taira(Shizuoka Cancer Center), Akira Ono(Shizuoka Cancer Center), Kazushige Wakuda(Shizuoka Cancer Center), Hisao Imai(Shizuoka Cancer Center), Takuya Oyakawa(Shizuoka Cancer Center), Takeshi Ishii, Shota Omori(Shizuoka Cancer Center), Kazuhisa Nakashima(Shizuoka Cancer Center), Masahiro Endo(MinebeaMitsumi (Japan)), Katsuhiro Omae(Shizuoka Cancer Center), Keita Mori(Shizuoka Cancer Center), Nobuyuki Yamamoto(Wakayama Medical University), Akira Tanuma, Toshiaki Takahashi(Shizuoka Cancer Center)
BMC Cancer
August 25, 2017
Cited by 76Open Access
Full Text

Abstract

Elderly patient with advanced cancer is one of the most vulnerable populations. Skeletal muscle depletion during chemotherapy may have substantial impact on their physical function. However, there is little information about a direct relationship between quantity of muscle and physical function. We sought to explore the quantitative association between skeletal muscle depletion, and muscle strength and walking capacity in elderly patients with advanced non–small cell lung cancer (NSCLC). Thirty patients aged ≥70 years with advanced NSCLC (stage III-IV) scheduled to initiate first-line chemotherapy were prospectively enrolled between January 2013 and November 2014. Lumbar skeletal muscle index (LSMI, cm2/m2), incremental shuttle walking distance (ISWD, m), and hand-grip strength (HGS, kg) were assessed at baseline, and 6 ± 2 weeks (T2) and 12 ± 4 weeks (T3) after study enrollment. Associations were analyzed using linear regression. Altogether, 11 women and 19 men with a median age of 74 (range, 70–82) years were included in the study; 24 received cytotoxic chemotherapy and 6, gefitinib. Mean ± standard deviation of LSMI, ISWD and HGS were 41.2 ± 7.8 cm2/m2, 326.0 ± 127.9 m, and 29.3 ± 8.5 kg, respectively. LSMI and ISWD significantly declined from baseline to T2 and T3. HGS significantly declined from baseline to T2 and T3 only in men. Change in LSMI was significantly associated with change in HGS (β = 0.3 ± 0.1, p = 0.0127) and ISWD (β = 8.8 ± 2.4, p = 0.0005). Skeletal muscle depletion accompanied with physical functional decline started in the early phase of the chemotherapy in elderly patients with advanced NSCLC. Our results suggest that there may be a need for early supportive care in these patients to prevent functional decline during chemotherapy. Trial registration number: UMIN000009768 Name of registry: UMIN (University hospital Medical Information Network). URL of registry: Date of registration: 14 January 2013. Date of enrolment of the first participant to the trial: 23 January 2013.


Related Papers

No related papers found

Powered by citation graph analysis